WONTECH Co., Ltd., a leader in laser and energy-based medical solutions, is unveiling its ‘next-generation’ healthcare solutions for the first time.
Through its participation at CES, WONTECH says it plans to expand its business scope beyond medical devices into the broader healthcare sector. The company aims to introduce innovative technologies that address key challenges in clinical environment, such as infection control, operational efficiency in healthcare facilities, and chronic pain management, thereby strengthening its mid- to long-term growth platform.
The company is launching PETRA & LIME, a non-contact biometric signal monitoring solution, and ELLISE, a converged pain treatment platform that combines laser technology with electrical stimulation. These solutions were developed using artificial intelligence, optical technology, and clinical validation.
PETRA & LIME enables non-contact measurement of vital biometric signals using cameras and video-based analysis. The solution was developed in response to heightened hygiene and infection-control standards in healthcare settings following the COVID pandemic. By eliminating direct patient contact, PETRA & LIME reduces the risk of cross-contamination, minimises device sterilisation and consumable management burdens, and improves overall clinical workflow efficiency and care environments.
ELLISE is a non-pharmacological, non-surgical pain treatment solution that integrates laser therapy with electrical stimulation. Designed as a complementary alternative to medication- or surgery-based treatments, ELLISE applies dual-wavelength laser energy and electrical stimulation simultaneously to enhance therapeutic effectiveness. The system precisely delivers energy to deep tissue layers associated with pain sources through the subcutaneous insertion of ultra-thin optical fiber needles.
In addition to these new solutions, WONTECH will also showcase its next-generation monopolar RF platform Oligio X, along with products from its subsidiary OneMedico, including Hairboom, LiftenS, Ultraskin S, OLIGIHOME, and Petite Glow. Through this expanded portfolio, spanning medical devices, healthcare, home care, and cosmetics—WONTECH will present a comprehensive view of its business expansion strategy.
A WONTECH representative said: “Our participation in CES 2026 marks an important starting point for WONTECH’s evolution from a medical device manufacturer into a healthcare solutions company that addresses real-world clinical challenges. Through CES, we aim to engage directly with a broad range of stakeholders, gain deeper insight into market needs, and continue enhancing our technological competitiveness to lead the global healthcare market.”
Currently, more than 60% of WONTECH’s total revenue is generated from overseas markets. The company holds major global regulatory approvals, including U.S. FDA, Australia TGA, CE (Europe), and Thailand FDA, and exports its products to over 80 countries worldwide. With subsidiaries in the United States, Japan, and Thailand, WONTECH continues to expand its global footprint and strengthen its international business infrastructure.
